(NASDAQ: SLNO) Soleno Therapeutics's forecast annual revenue growth rate of 116.83% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 289.31%, and while it is forecast to beat the US market's average forecast revenue growth rate of 58.77%.
Soleno Therapeutics's revenue in 2025 is $98,675,000.On average, 13 Wall Street analysts forecast SLNO's revenue for 2025 to be $9,884,793,001, with the lowest SLNO revenue forecast at $8,985,150,082, and the highest SLNO revenue forecast at $10,642,104,354. On average, 13 Wall Street analysts forecast SLNO's revenue for 2026 to be $25,291,513,672, with the lowest SLNO revenue forecast at $18,506,863,314, and the highest SLNO revenue forecast at $31,758,737,783.
In 2027, SLNO is forecast to generate $39,516,613,794 in revenue, with the lowest revenue forecast at $25,644,925,637 and the highest revenue forecast at $47,033,868,893.